The rapid emergence of GLP-1 receptor agonists into obesity management is fundamentally reshaping the metabolic health landscape.
In major clinical trials, Semaglutide has demonstrated average weight losses of approximately 15%, while higher doses of Tirzepatide have approached 20%.1
With millions of individuals now using GLP-1 therapies globally, and forecasts projecting continued growth through 2030 and beyond, the implications for other health categories are significant.2